Mutations in TP53 gene are associated with deletion of chromosome 17. This is indicative of poor prognosis in Multiple Myeloma (MM) cases. Early cases of MM may not show this deletion but as disease advances, 17p deletion can be detected. Screening for 17p deletion in MM cases aids management decisions & directs these high risk patients towards alternative therapies. This deletion has also been detected in Chronic Lymphocytic Leukemia (CLL) & is associated with poor prognosis.